Publication at First Faculty of Medicine |
2013
Abstract
A case report of a patient with multiple sclerosis diagnosed in 1996 illustrates the impact of delayed biological treatment intervention on patient prognosis. Interferon beta therapy initiated after more than 10 years of immunosuppressive treatment including cyclophosphamide and mitoxantrone was entirely ineffective, the inflammatory activity continued, and the patient was finally switched to escalation regimen with natalizumab.
Although the disease course could potentially be assessed as secondary progressive with the presence of inflammatory activity, her neurological status improved by 2.0 points on the Kurtzke Expanded Disability Status Scale during the first year of natalizumab treatment